TY - JOUR T1 - Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon? JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 940 LP - 941 DO - 10.1136/annrheumdis-2013-204009 VL - 73 IS - 5 AU - Francesca Ingegnoli AU - Roberta Gualtierotti AU - Tommaso Schioppo AU - Annalisa Orenti AU - Patrizia Boracchi AU - Chiara Lubatti AU - Claudio Mastaglio AU - Valentina Galbiati AU - Antonella Murgo AU - Silvana Zeni AU - Claudia Grossi AU - Orietta Borghi AU - William Rosenberg AU - Laura Castelnovo AU - Luigi Meroni Pier Y1 - 2014/05/01 UR - http://ard.bmj.com/content/73/5/940.abstract N2 - Raynaud's phenomenon (RP) can be the first manifestation or may be present before the development of an overt systemic sclerosis (SSc).1 Enhanced liver fibrosis (ELF) test, an algorithm combining tissue inhibitors of matrix metalloproteinases (TIMP-1), hyaluronic acid (HA) and aminoterminal propeptide of type III procollagen (PIIINP), has been related to several measures of fibrosis in SSc patients.2–⇓4 We evaluated whether these biomarkers could discriminate between primary and secondary RP. Consecutive adult patients with RP at the first rheumatologic evaluation were recruited from February 2011 to May 2012 with ethics committee approval. Exclusion criteria were history of any fibrosing disorder, organ transplantation, hepatocellular carcinoma or treatment with interferon. One patient was excluded for interferon treatment. Fifteen limited cutaneous SSc and 15 diffuse … ER -